Carrie Fowlie is the CEO of Hepatitis Australia, the national peak body representing the state and territory hepatitis organisations and the interests of 350,000 Australians impacted by viral hepatitis. Carrie has two decades of peak body, policy and social justice experience. Her collaborative work has resulted in policy, programs and law reform consistent with the evidence and the priorities of her constituencies.

Dr. Gane is Professor of Medicine at the University of Auckland, New Zealand, and Lead Hepatologist and Deputy Director of the New Zealand Liver Unit at Auckland City Hospital. Dr Gane chairs the Ministry of Health committee responsible for HCV elimination and co-wrote the first New Zealand National HepC Action Plan. He is an investigator for many international clinical trials with particular interest in early phase development of new direct acting antiviral therapies against chronic hepatitis C, hepatitis B, NASH and HCC. He has published over 600 papers in peer-reviewed journals. Dr Gane is current Associate Editor for the Journal of Hepatology In 2011, Dr Gane received the New Zealand Health Research Council (NZHRC) annual Beaven Medal and in 2014, the NZHRC annual Liley Medal. In 2011, Dr. Gane was awarded Member of the Order of New Zealand and in 2017, was named as New Zealand Innovator of the Year for his work towards HCV elimination in New Zealand.

Nafisa Yussf is a Researcher at the WHO Collaborating Centre for Viral Hepatitis, The Doherty Institute. Her background is in community engagement and public health research. She is passionate about health equity and improving the lives of people affected by hepatitis B.

Mim O’Flynn is a registered nurse with a long history of working with patients living with HIV and Hepatitis. With extensive experience in outreach fibroscan, her current focus is screening and linking marginalised and incarcerated patients to Hepatitis C care, as the Kombi Clinic Nurse.